The number two French laboratory has returned to the red for the 2022/2023 financial year, recording a net loss of 623 million euros. Its conviction by the Court of Appeal on December 20, 2023 in the Mediator case “generates a loss of 450 million euros” The laboratory, which targets difficult-to-treat cancers, continues its rise in oncology, which now represents 20.2% of turnover, compared to 17.4% during the previous financial year.